SEC INSIDER TRANSACTIONS

AbbVie Inc. (ABBV) Insider Transactions

Explore official ownership filings, with every record linked to its source.

Reported data · not live

ABBV · AbbVie Inc.

Filing window SEC codes (comma separated) Security type Order

More transaction filters

Roles: director,officer,ten_percent_owner,otherOwner nameOfficer titleOwnership: D, I, unknownoriginal or amendedTransaction fromTransaction throughFiled fromFiled throughMinimum quantityMaximum quantityMinimum priceMaximum priceMinimum calculated valueMaximum calculated valueResults per page (1–100)

OR within codes/roles; AND between categories. Roles apply to buyers and sellers. Owner predicates match the same owner. Missing values fail numeric/date filters. Value is quantity × reported price for non-derivative rows only; derivative values are unknown. Amendments stay separate; joint owners do not duplicate rows.

Reset filters

Active filters: days=6m

Stale snapshot · Covered: filings 2026-05-14 to 2026-11-13 · 7 filings · fetched 2026-11-13T16:19:07Z

Recent reported activity

0purchase rows on this page

2sale rows on this page

13matching filing rows

Purchases and sales count original non-derivative P and S rows. Awards, gifts, exercises, derivatives and amendments are shown separately and are not described as market purchases.

Transaction / filed	Reporting owner(s)	Code / security	Quantity	Price as filed	Ownership	Source
2026-11-12Filed 2026-11-12	Stewart Jeffrey RyanOfficer · EVP, CHIEF COMMERCIAL OFFICER Filing context Reported filing row; may be amended. Do not sum filings blindly. F1 The price reported in column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $293.54 to $293.82, inclusive. The reporting person undertakes to provide AbbVie Inc., any security holder of AbbVie Inc. or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote F2 The reporting person disclaims beneficial ownership of all securities held by his spouse. F3 Employee stock option granted pursuant to the AbbVie Amended and Restated 2013 Incentive Stock Program in a transaction exempt from Section 16 under Rule 16b-3. The option became exercisable in annual increments of 5,357 on February 15, 2019, 5,356 on February 15, 2020, and 5,357 on February 15, 2021. F4 Employee stock option granted pursuant to the AbbVie Amended and Restated 2013 Incentive Stock Program in a transaction exempt from Section 16 under Rule 16b-3. The option became exercisable in annual increments of 16,367 on February 20, 2021, 16,366 on February 20, 2022, and 16,366 on February 20, 2023. References:	G GiftCommon Stock, $0.01 par value · Non-derivative	3,450D	0	Direct	Form 4 ↗0001761675-26-000007
2026-11-09Filed 2026-11-12	Stewart Jeffrey RyanOfficer · EVP, CHIEF COMMERCIAL OFFICER Filing context Reported filing row; may be amended. Do not sum filings blindly. F1 The price reported in column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $293.54 to $293.82, inclusive. The reporting person undertakes to provide AbbVie Inc., any security holder of AbbVie Inc. or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote F2 The reporting person disclaims beneficial ownership of all securities held by his spouse. F3 Employee stock option granted pursuant to the AbbVie Amended and Restated 2013 Incentive Stock Program in a transaction exempt from Section 16 under Rule 16b-3. The option became exercisable in annual increments of 5,357 on February 15, 2019, 5,356 on February 15, 2020, and 5,357 on February 15, 2021. F4 Employee stock option granted pursuant to the AbbVie Amended and Restated 2013 Incentive Stock Program in a transaction exempt from Section 16 under Rule 16b-3. The option became exercisable in annual increments of 16,367 on February 20, 2021, 16,366 on February 20, 2022, and 16,366 on February 20, 2023. References: F4	M Exercise / conversionOption (Right to Buy) · Derivative	24,549D	0	Direct	Form 4 ↗0001761675-26-000007
2026-11-09Filed 2026-11-12	Stewart Jeffrey RyanOfficer · EVP, CHIEF COMMERCIAL OFFICER Filing context Reported filing row; may be amended. Do not sum filings blindly. F1 The price reported in column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $293.54 to $293.82, inclusive. The reporting person undertakes to provide AbbVie Inc., any security holder of AbbVie Inc. or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote F2 The reporting person disclaims beneficial ownership of all securities held by his spouse. F3 Employee stock option granted pursuant to the AbbVie Amended and Restated 2013 Incentive Stock Program in a transaction exempt from Section 16 under Rule 16b-3. The option became exercisable in annual increments of 5,357 on February 15, 2019, 5,356 on February 15, 2020, and 5,357 on February 15, 2021. F4 Employee stock option granted pursuant to the AbbVie Amended and Restated 2013 Incentive Stock Program in a transaction exempt from Section 16 under Rule 16b-3. The option became exercisable in annual increments of 16,367 on February 20, 2021, 16,366 on February 20, 2022, and 16,366 on February 20, 2023. References: F3	M Exercise / conversionOption (Right to Buy) · Derivative	16,070D	0	Direct	Form 4 ↗0001761675-26-000007
2026-11-09Filed 2026-11-12	Stewart Jeffrey RyanOfficer · EVP, CHIEF COMMERCIAL OFFICER Filing context Reported filing row; may be amended. Do not sum filings blindly. F1 The price reported in column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $293.54 to $293.82, inclusive. The reporting person undertakes to provide AbbVie Inc., any security holder of AbbVie Inc. or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote F2 The reporting person disclaims beneficial ownership of all securities held by his spouse. F3 Employee stock option granted pursuant to the AbbVie Amended and Restated 2013 Incentive Stock Program in a transaction exempt from Section 16 under Rule 16b-3. The option became exercisable in annual increments of 5,357 on February 15, 2019, 5,356 on February 15, 2020, and 5,357 on February 15, 2021. F4 Employee stock option granted pursuant to the AbbVie Amended and Restated 2013 Incentive Stock Program in a transaction exempt from Section 16 under Rule 16b-3. The option became exercisable in annual increments of 16,367 on February 20, 2021, 16,366 on February 20, 2022, and 16,366 on February 20, 2023. References: F1	S Sale (market/private)Common Stock, $0.01 par value · Non-derivative	40,619D	293.6	Direct	Form 4 ↗0001761675-26-000007
2026-11-09Filed 2026-11-12	Stewart Jeffrey RyanOfficer · EVP, CHIEF COMMERCIAL OFFICER Filing context Reported filing row; may be amended. Do not sum filings blindly. F1 The price reported in column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $293.54 to $293.82, inclusive. The reporting person undertakes to provide AbbVie Inc., any security holder of AbbVie Inc. or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote F2 The reporting person disclaims beneficial ownership of all securities held by his spouse. F3 Employee stock option granted pursuant to the AbbVie Amended and Restated 2013 Incentive Stock Program in a transaction exempt from Section 16 under Rule 16b-3. The option became exercisable in annual increments of 5,357 on February 15, 2019, 5,356 on February 15, 2020, and 5,357 on February 15, 2021. F4 Employee stock option granted pursuant to the AbbVie Amended and Restated 2013 Incentive Stock Program in a transaction exempt from Section 16 under Rule 16b-3. The option became exercisable in annual increments of 16,367 on February 20, 2021, 16,366 on February 20, 2022, and 16,366 on February 20, 2023. References:	M Exercise / conversionCommon Stock, $0.01 par value · Non-derivative	24,549A	93.5	Direct	Form 4 ↗0001761675-26-000007
2026-11-09Filed 2026-11-12	Stewart Jeffrey RyanOfficer · EVP, CHIEF COMMERCIAL OFFICER Filing context Reported filing row; may be amended. Do not sum filings blindly. F1 The price reported in column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $293.54 to $293.82, inclusive. The reporting person undertakes to provide AbbVie Inc., any security holder of AbbVie Inc. or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote F2 The reporting person disclaims beneficial ownership of all securities held by his spouse. F3 Employee stock option granted pursuant to the AbbVie Amended and Restated 2013 Incentive Stock Program in a transaction exempt from Section 16 under Rule 16b-3. The option became exercisable in annual increments of 5,357 on February 15, 2019, 5,356 on February 15, 2020, and 5,357 on February 15, 2021. F4 Employee stock option granted pursuant to the AbbVie Amended and Restated 2013 Incentive Stock Program in a transaction exempt from Section 16 under Rule 16b-3. The option became exercisable in annual increments of 16,367 on February 20, 2021, 16,366 on February 20, 2022, and 16,366 on February 20, 2023. References:	M Exercise / conversionCommon Stock, $0.01 par value · Non-derivative	16,070A	114.36	Direct	Form 4 ↗0001761675-26-000007
2026-09-30Filed 2026-10-02	RAPP EDWARD JDirector Filing context Reported filing row; may be amended. Do not sum filings blindly. F1 Director fees credited to a stock equivalent unit account under the director's grantor trust are distributed over a period equal to the director's years of board service, generally commencing at the later of age 65 or upon retirement from the board. The stock equivalent units earn the same return as if the fees were invested in AbbVie stock. F2 Balance includes stock equivalent units acquired pursuant to a dividend reinvestment feature. References: F1, F2	A Award / grantStock Equivalent Units · Derivative	129A	261.59	Direct	Form 4 ↗0001171780-26-000014
2026-09-30Filed 2026-10-02	Quaggin Susan EDirector Filing context Reported filing row; may be amended. Do not sum filings blindly. F1 Director fees credited to an unfunded book account in the director's name are distributed over a period equal to the director's years of board service, generally commencing at the later of age 65 or upon retirement from the board. The stock equivalent units earn the same return as if the fees were invested in AbbVie stock. F2 Balance includes stock equivalent units acquired pursuant to a dividend reinvestment feature. References: F1, F2	A Award / grantStock Equivalent Units · Derivative	59A	261.59	Direct	Form 4 ↗0001997505-26-000010
2026-08-14Filed 2026-08-18	Donoghoe NicholasOfficer · EVP, CHIEF BUS/STRAT OFFICER Filing context Reported filing row; may be amended. Do not sum filings blindly. F1 Employee stock option granted pursuant to the AbbVie Amended and Restated 2013 Incentive Stock Program in a transaction exempt from Section 16 under Rule 16b-3. The option became exercisable in annual increments of 10,904 on February 21, 2020, 10,903 on February 21, 2021, and 10,903 on February 21, 2022. References: F1	M Exercise / conversionOption (Right to buy) · Derivative	32,710D	0	Direct	Form 4 ↗0001762951-26-000006
2026-08-14Filed 2026-08-18	Donoghoe NicholasOfficer · EVP, CHIEF BUS/STRAT OFFICER Filing context Reported filing row; may be amended. Do not sum filings blindly. F1 Employee stock option granted pursuant to the AbbVie Amended and Restated 2013 Incentive Stock Program in a transaction exempt from Section 16 under Rule 16b-3. The option became exercisable in annual increments of 10,904 on February 21, 2020, 10,903 on February 21, 2021, and 10,903 on February 21, 2022. References:	S Sale (market/private)Common Stock, $0.01 par value · Non-derivative	32,710D	250	Direct	Form 4 ↗0001762951-26-000006
2026-08-14Filed 2026-08-18	Donoghoe NicholasOfficer · EVP, CHIEF BUS/STRAT OFFICER Filing context Reported filing row; may be amended. Do not sum filings blindly. F1 Employee stock option granted pursuant to the AbbVie Amended and Restated 2013 Incentive Stock Program in a transaction exempt from Section 16 under Rule 16b-3. The option became exercisable in annual increments of 10,904 on February 21, 2020, 10,903 on February 21, 2021, and 10,903 on February 21, 2022. References:	M Exercise / conversionCommon Stock, $0.01 par value · Non-derivative	32,710A	79.02	Direct	Form 4 ↗0001762951-26-000006
2026-06-30Filed 2026-07-02	RAPP EDWARD JDirector Filing context Reported filing row; may be amended. Do not sum filings blindly. F1 Director fees credited to a stock equivalent unit account under the director's grantor trust are distributed over a period equal to the director's years of board service, generally commencing at the later of age 65 or upon retirement from the board. The stock equivalent units earn the same return as if the fees were invested in AbbVie stock. F2 Balance includes stock equivalent units acquired pursuant to a dividend reinvestment feature. References: F1, F2	A Award / grantStock Equivalent Units · Derivative	134A	251.64	Direct	Form 4 ↗0001171780-26-000012
2026-06-30Filed 2026-07-02	Quaggin Susan EDirector Filing context Reported filing row; may be amended. Do not sum filings blindly. F1 Director fees credited to an unfunded book account in the director's name are distributed over a period equal to the director's years of board service, generally commencing at the later of age 65 or upon retirement from the board. The stock equivalent units earn the same return as if the fees were invested in AbbVie stock. F2 Balance includes stock equivalent units acquired pursuant to a dividend reinvestment feature. References: F1, F2	A Award / grantStock Equivalent Units · Derivative	62A	251.64	Direct	Form 4 ↗0001997505-26-000008

Imported instruments only. Joint owners do not multiply transactions. Amendments are separate filing rows, not additional trades. No aggregate trade totals are implied.